News

The Yield Results of the Second Commercial Production Run for AKUUGO🄬 Suspension for Intracranial Implantation

The Results of the First Commercial Production Run to Meet the Approval Conditions for the Shipment of AKUUGO🄬 Suspension for Intracranial Implantation

Positive Results of Key Development Product SB623 for Chronic Effects of Traumatic Brain Injury, including Sustained Motor Function Improvement up to 48 weeks, published in Neurology

SanBio Obtains Marketing Approval for “AKUUGO🄬 Suspension for Intracranial Implantation” (INN: Vandefitemcel) as a Therapeutic Agent for Improving Chronic Motor Paralysis From Traumatic Brain Injury (TBI)

Notice Concerning Notice of Allowance of New Patent for Cell Therapy Using SB623 for Chronic Ischemic Stroke in the US

[Results of Basic Research] Publication of an Article on the Neuronal Activity and Network Formation Promotion of the Key Development Product SB623

Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan

Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan

Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan

Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan

On April 7, NeurologyLive published an interview with Dr. Peter McAllister regarding the final analysis of the Phase 2 STEMTRA trial.

Dr. Damien Bates, Chief Medical Officer and Head of Research at SanBio, publishes report in the leading medical journal, Stroke

MORI, President & CEO, will be a panelist at “Navigating Biopharma Innovation Across the Pacific” hosted by the U.S. Embassy and the Japan Society of Northern California on November 11

Presentation of Phase 2 STEMTRA Trial Results at The 14th World Congress on Brain Injury

Head of Regulatory Affairs Japan, Kazumi Sawaguchi, Ph.D., gave a presentation at 5th DIA Cell and Gene Therapy Products Symposium in Japan

SanBio to Present at the 39th Annual J.P. Morgan Healthcare Conference

Message from Representative Director and President, Keita Mori, regarding disclosures made on December 13, 2019

【Announcement】SanBio will present at the 37th Annual J.P. Morgan Healthcare Conference

SanBio presented at the 36th Annual J.P. Morgan Healthcare Conference

Keita Mori, CEO of SanBio will speak at 2017 World Alliance Forum in San Francisco on November30

SanBio will present at 2nd DIA Cell Therapy Products Symposium in Japan on December 15"Quality of Regenerative Medical Products -What do we need to start a clinical study in Japan? -" Takehiko Kaneko, Medical Director & Head of Clinical Development Japan, SanBio Co., Ltd.